Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSV-FH
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intrahepatic (preclinical), Intravenous (experimental/preclinical)
01
Overview
VSV-FH is a **recombinant oncolytic virus** created by replacing the native glycoprotein (G) gene in vesicular stomatitis virus (VSV) with the genes encoding the fusion (F) and hemagglutinin (H) envelope proteins of measles virus[1][2][4]. This chimeric virus selectively targets and infects cancer cells overexpressing CD46, a cellular receptor commonly upregulated in various malignancies. VSV-FH exhibits improved tumor selectivity and robust oncolytic activity through induction of cell fusion (syncytia formation) and rapid replication, integrating anti-cancer mechanisms of both parental viruses: **rapid lytic apoptosis (VSV)** and **syncytia-mediated cell death (measles virus)**[1][2][3][4]. Preclinical studies demonstrate superior tumor cell killing, rapid propagation, and diminished neurotoxicity compared to parental VSV in hepatocellular carcinoma, myeloma, and other solid tumor models. Additional modifications have allowed further tumor targeting, such as retargeting the virus to specific tumor-associated receptors[4].
- Brand names
- VSV-FH
- Other names
- recombinant vesicular stomatitis virus-fusion and hemagglutinin
02
Targets
CD46 (CD46 Molecule)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PVRL4 (Nectin cell adhesion molecule 4)SLAMF1 (SLAM family member 1)
Beyond the preview
Go deeper on VSV-FH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSV-FH.